Although preclinical studies suggest that targeting glutamine pathways—such as through glutaminase inhibition—can suppress tumor progression and neovascularization, the clinical relevance of these findings in the context of perioperative supplementation remains uncertain [185]. This evidence concerns the gene GLS and neoplasm.